An Immunotherapy Renaissance in Hepatobiliary Cancers

Immunotherapy combination improves survival in advanced liver ...

The addition of nivolumab to ipilimumab significantly improved OS among adults with previously untreated advanced hepatocellular carcinoma, ...

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Hepatocellular carcinoma (HCC) can have viral or non-viral causes1–5. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC.

Management and Treatment of Hepatocellular Carcinoma with ...

Immunotherapy has recently become a promising method for inhibiting HCC tumor progression, recurrence, and metastasis.

Immunotherapy for hepatobiliary cancers: Emerging targets and ...

Immunotherapy, as an emerging treatment approach, represents an effective and promising option against PLC. However, the selection of ...

Efficacy of immunotherapy in hepatocellular carcinoma: Does liver ...

The systemic treatment of hepatocellular carcinoma (HCC) is changing rapidly. After a decade of tyrosine kinase inhibitors (TKIs), ...

Immunotherapy in hepatocellular carcinoma: How does underlying ...

Data suggest that the surrounding liver milieu may influence tumour response. In addition, different aetiologies of HCC and their effects on the ...

Application of immune checkpoint inhibitors in hepatobiliary cancers

Unlike HCC, clinical studies have found that immunotherapy is effective only for BTC with specific molecular markers. Moreover, the molecular ...

Treating Hepatobiliary Cancer: The Immunologic Approach

Immunotherapy has been tested in hepatobiliary cancers for many years, particularly HCC. Most studies in the past have either used cytokine ...

What Is Hepatocellular Carcinoma? - Imfinzi

IMFINZI combined with one dose of IMJUDO is an immunotherapy treatment for people with unresectable hepatocellular carcinoma (uHCC). IMFINZI and IMJUDO are ...

2022 Peer Reviewed Cancer Highlight - A Promising Nanotech ...

Hepatocellular carcinoma (HCC) accounts for 75%-85% of all cases of liver cancer. With the advent of immunotherapy (immune checkpoint blockade [ ...

Immunotherapy for the treatment of biliary tract cancer: an evolving ...

In this review, we discuss the systemic therapeutic advances for BTC over the past decade, the rationale for immunotherapy in BTC, prior trials utilizing IO in ...

For Patients - Immunotherapy in the Liver & Pancreas

While emerging immunotherapies have improved patient outcomes in some types of cancer, unfortunately, patients with certain tumors, including the liver and ...

Is Immunotherapy Still the Best Option for Advanced Liver Cancer ...

Patients with advanced liver cancer and poor liver function have a lower degree of benefit from immune checkpoint inhibitors than patients who have better ...

Immunotherapy for children with primary liver carcinomas

Could immunotherapy benefit pediatric liver carcinoma? New research suggests checkpoint inhibitors might be an effective treatment option.

How TECENTRIQ Immunotherapy Is Thought to Work for HCC

... (bevacizumab) work as a combination immunotherapy against hepatocellular carcinoma (HCC), a type of liver cancer. See full safety for more information.

Microsatellite instability and immune checkpoint inhibitors

This new indication marks a paradigm shift in the therapeutic strategy of cancers; however, when considering the optimum indication for ICIs and ...

Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced ...

Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancer. Due to late-stage diagnosis, most patients with HCC are ...

Liver Field during Immunotherapy of Hepatocellular Carcinoma

Promotion of carcinogenesis mediated by CD8+PD1+ lymphocytes could be prevented by CD8+ cells depletion or inhibition of tumor necrosis factor, ...

Treatments for stage C liver cancer

You may be offered immunotherapy for stage C liver cancer. Pembrolizumab (Keytruda) may be offered if you have already had treatment with sorafenib or are ...

Hepatocellular Carcinoma Treatment Protocols - Medscape Reference

Sorafenib, an oral multikinase inhibitor, has shown the most benefit in patients with Child-Pugh class A, with very limited data on patients ...